Merck has agreed to pay up to $400 million to acquire IOmet Pharma, a Scottish company that specializes in the development of small molecule-based cancer treatments.

IOmet will operate as a division of Merck. The acquisition will include IOmet’s pre-clinical pipeline of IDO (indoleamine-2,3-dioxygenase 1), TDO (tryptophan-2,3-dioxygenase), and dual-acting IDO/TDO inhibitors.

…source…